MBNL1 regulates essential alternative RNA splicing patterns in MLL-rearranged leukemia

Itskovich, Svetlana S.; Gurunathan, Arun; Clark, Jason; Burwinkel, Matthew; Wunderlich, Mark; Berger, Mikaela R.; Kulkarni, Aishwarya; Chetal, Kashish; Venkatasubramanian, Meenakshi; Salomonis, Nathan; Kumar, Ashish R.; Lee, Lynn H.

doi:10.1038/s41467-020-15733-8

Download PDF

Article
Open access
Published: 12 May 2020

MBNL1 regulates essential alternative RNA splicing patterns in MLL-rearranged leukemia

Nature Communications volume 11, Article number: 2369 (2020) Cite this article

9019 Accesses
35 Citations
6 Altmetric
Metrics details

Subjects

A Publisher Correction to this article was published on 07 July 2020

This article has been updated

Abstract

Despite growing awareness of the biologic features underlying MLL-rearranged leukemia, targeted therapies for this leukemia have remained elusive and clinical outcomes remain dismal. MBNL1, a protein involved in alternative splicing, is consistently overexpressed in MLL-rearranged leukemias. We found that MBNL1 loss significantly impairs propagation of murine and human MLL-rearranged leukemia in vitro and in vivo. Through transcriptomic profiling of our experimental systems, we show that in leukemic cells, MBNL1 regulates alternative splicing (predominantly intron exclusion) of several genes including those essential for MLL-rearranged leukemogenesis, such as DOT1L and SETD1A. We finally show that selective leukemic cell death is achievable with a small molecule inhibitor of MBNL1. These findings provide the basis for a new therapeutic target in MLL-rearranged leukemia and act as further validation of a burgeoning paradigm in targeted therapy, namely the disruption of cancer-specific splicing programs through the targeting of selectively essential RNA binding proteins.

The RNA-binding protein IGF2BP3 is critical for MLL-AF4-mediated leukemogenesis

Article Open access 29 July 2021

The splicing factor RBM17 drives leukemic stem cell maintenance by evading nonsense-mediated decay of pro-leukemic factors

Article Open access 04 July 2022

Complex landscape of alternative splicing in myeloid neoplasms

Article 04 August 2020

Introduction

Reciprocal chromosomal translocations of the mixed lineage leukemia (MLL) gene with one of over 70 fusion partners are commonly found in a subset of aggressive leukemias including infant leukemia, and are associated with poor outcome^1,2,3. Regardless of the fusion partner and the type of leukemia (acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL)) all MLL-rearranged leukemias share a common gene expression profile that is distinct from that of non⁻MLL-rearranged leukemias^4,5. Analysis of MLL-rearranged signatures reveals that muscleblind-like 1 (MBNL1) is one of the most consistently overexpressed genes in MLL-rearranged leukemia compared to other leukemias^3,4,5,6.

Muscleblind-like 1 (MBNL1) is an RNA-binding protein that has been shown to regulate RNA alternative splicing, localization, and integrity^7,8,9,10,11. Alternative splicing of pre-mRNA is a key mechanism regulating eukaryotic gene expression by expanding genome coding diversity. MBNL1 has previously been shown to regulate alternative splicing in the fetal-to-adult transition in heart, muscle, and brain⁹. Sequestration of MBNL1 due to binding to expanded poly-CUG repeats in the dystrophia myotonica protein kinase (DMPK) mRNA is a main contributor to the pathogenesis of myotonic dystrophy type 1 (DM1), a syndrome characterized by muscle weakness, cardiac abnormalities, intellectual disability, and cataracts. The sequestration of MBNL1 results in missplicing of target mRNAs, leading to the clinical features¹². Moreover, MBNL1 and MBNL2 are known to play a central role in regulating the pattern of alternative splicing events that control embryonic cell pluripotency¹³. Knockdown of Mbnl1 in murine fetal liver cells leads to blockade of terminal erythropoiesis through deregulation of alternative splicing of Ndel1 mRNA¹⁴.

Abnormalities in RNA processing, particularly splicing, have been associated with cancer, including AML and ALL)independent of spliceosome mutations^{15,16,17,18,19}. The increased expression of MBNL1 in MLL-rearranged leukemia described above, as well as evidence that the MLL-fusion complex directly binds the MBNL1 promoter²⁰, suggest that MBNL1-mediated RNA splicing may be important to the pathogenesis of MLL-rearranged leukemias. The mechanism of action and extent of essentiality of MBNL1 in MLL-rearranged leukemogenesis, however, remains unknown.

In this report, through a combination of functional genomic studies, pharmacologic inhibition, and comprehensive analysis of alternative splicing we demonstrate that MBNL1 is required in MLL-rearranged leukemia.

Results

MBNL1 is required for the propagation of human MLL-rearranged leukemia in vitro and in vivo

To confirm the relevance of MBNL1 expression in MLL-rearranged leukemia, we first compared multiple gene expression studies which identified differentially expressed genes between MLL-rearranged and MLL-wildtype leukemias^4,6,21,22. We began by examining the intersection of these gene expression signatures, and found that MBNL1 expression was a common feature of these signatures across both acute myeloid and lymphoblastic leukemias (Fig. 1a). We further examined MBNL1 expression across two major primary patient datasets evaluating both AML and ALL, and consistently found high MBNL1 expression in MLL-rearranged patient samples^{23,24,25,26,27,28} (Supplementary Figs. 1A–C). We subsequently analyzed expression levels of MBNL1 by quantitative RT-PCR (qRT-PCR) in human leukemia cell lines. We found MBNL1 expression in all leukemic cell lines tested, with the highest MBNL1 expression in MLL-rearranged cell lines (Fig. 1b). Additionally, human CD34⁺ cord blood transformed with the MLL-AF9 (MA9) oncogene demonstrated higher levels of MBNL1 expression compared to normal CD34⁺ cord blood cells (Supplementary Fig. 1D). A similar phenomenon was observed in Lin- mouse bone marrow cells transduced with the MA9 retrovirus (Supplementary Fig. 1E) MBNL1 was recently demonstrated to be a direct target of the MLL-AF4 fusion protein in patient-derived ALL cell lines as well as in an experimental retroviral model^20,29. To determine whether this observation applied to leukemia cells bearing different MLL-fusion partners, we analyzed MLL-fusion protein (MLL-N and fusion partner C-terminus if applicable) and H3K79me2 chromatin immunoprecipitation followed by deep sequencing (ChIP-seq) datasets from THP-1³⁰ and ML-2³¹ cell lines (with MLL-AF9 and MLL-AF6 respectively), as well as from the MV4;11³⁰, RS4;11³², and SEM³³ cell lines which bear an MLL-AF4 fusion. We found evidence of MLL-N/fusion-C binding to the MBNL1 promoter and gene body, along with H3K79me2 enrichment across all cell lines studied (Fig. 1c). To experimentally verify the observed interactions between MLL-fusion proteins and MBNL1, we used transformed human CD34⁺ cells bearing a repressible MA9 oncogene where doxycycline treatment represses MA9 expression^34,35. Nuclear extracts isolated at different intervals demonstrated a decrease in MBNL1 expression directly correlating with MA9 downregulation (Fig. 1d).

**Fig. 1: MBNL1 is overexpressed in MLL-rearranged leukemias and MLL-fusion proteins interact with MBNL1.**

We then performed short hairpin RNA (shRNA) knockdown studies of MBNL1 in human leukemia cell lines to test its requirement for leukemia cell growth. We screened commercially available lentiviral shRNAs and chose two that showed the most consistent and efficient knockdown of MBNL1 mRNA (Supplementary Fig. 2A) and protein (Fig. 2a), hereafter referred to as shMBNL1-64 and -65. There was substantial growth inhibition of MLL-rearranged cell lines following MBNL1 knockdown both in liquid culture (Fig. 2b–d) and in colony forming unit (CFU) assays (Supplementary Figs. 2B–C). However, MBNL1 knockdown did not significantly affect growth of non-MLL-rearranged leukemic cells (Fig. 2e–g) bearing a variety of different oncofusions (BCR-ABL in K562, RUNX1-RUNXT1 in Kasumi-1) despite efficient knockdown (Supplementary Fig. 2D–H).

**Fig. 2: MBNL1 is required for the propagation of human MLL-rearranged leukemia in vitro and in vivo.**

To determine the requirement for MBNL1 in leukemia in vivo, we transduced two primary patient AML samples bearing MLL fusions (one MLL-AF9 and one MLL-AF10) with shMBNL1-64 or a non-targeting (NT) control. Transduction efficiency ranged from 67 to 85% (Venus⁺). Bulk cells were transplanted into immune-deficient NSGS mice. At the time of visible illness, all mice showed robust human cell engraftment (ranging from 92.4 to 99.4% in the MLL-AF9 group and 7.6–40.2% in the MLL-AF10 group) in the bone marrow. Bone marrow from mice transplanted with shNT-transduced cells contained Venus⁺ cells (range 6.9–78% of all human cells), whereas the majority of mice transplanted with shMBNL1-64 had virtually no Venus⁺ fraction (Fig. 2h). One mouse transplanted with shMBNL1-64-transduced MLL-AF9 patient cells had 62.4% Venus⁺; this mouse was removed from analysis after qRT-PCR analysis revealed lack of MBNL1 knockdown. To show broad applicability of knockdown, we repeated this experiment using an MLL-AF9/NRAS^G12D cell line, with similar results (Supplementary Fig. 3A–C)³⁶. These data suggest that MBNL1 is essential for leukemia propagation in vivo.

As an alternative approach, we tested the effects of MBNL1 inhibition achieved by biochemical means. Recently, an MBNL1-specific inhibitor that prevents MBNL1 binding to its targets was identified in a high-throughput screen for compounds with activity in myotonic dystrophy³⁷. We tested the effect of this compound on MLL-rearranged (MV4;11, MOLM13) and non-MLL-rearranged leukemia cell lines (HL-60, K562, Kasumi-1), as well as on normal CD34⁺ cord blood cells. Cells were incubated with the inhibitor at various concentrations (based on previous experiments). Leukemia cells were sensitive to the inhibitor treatment as evidenced by a decrease in cell viability within 18 h in a variety of leukemia cell lines. Despite the high concentrations necessary to achieve the observed effects, MLL-rearranged leukemia cells demonstrated comparatively higher sensitivity to the compound (Fig. 2i, j).

MLL-AF9 leukemia is delayed in Mbnl1 knockout (KO) mice

As a complementary means of characterizing the essentiality of MBNL1 in MLL-rearranged leukemia, we used a mouse model of Mbnl1 genetic ablation. For these experiments we used Mbnl1^∆E3/∆E3 (Mbnl1^−/−) KO mice lacking Mbnl1 exon 3 (kindly provided by Dr. Maurice Swanson)³⁸. We transduced Mbnl1^−/− and littermate control (Mbnl1^+/+) lineage-negative bone marrow cells with an MLL-AF9 GFP-bearing retrovirus³⁴. Four days after transduction, Mbnl1^+/+ and Mbnl1^−/− cells were plated in semi-solid culture for at least two weekly serial rounds to select transformed cells, which were subsequently transplanted into syngeneic irradiated mice (Fig. 3a). Moribund animals were classified as having developed leukemia at necropsy based on the presence of splenomegaly, elevated white blood cell count in the peripheral blood, and leukemic cell infiltration in the bone marrow and spleen. In these experimental settings, mice transplanted with transformed Mbnl1^+/+ cells developed leukemia with a median time of 84 days. However, mice transplanted with transformed Mbnl1^−/− cells demonstrated a significantly prolonged latency and leukemia-free survival of 123 days after transplantation (Fig. 3b). Both groups showed comparable levels of splenomegaly, high white blood cell counts, anemia, and thrombocytopenia. To characterize the influence of Mbnl1 loss on leukemia-initiating cells in vivo we performed secondary transplantation into irradiated hosts using splenocytes from sick primary mice. Similar to our primary transplant experiments, secondary recipients of Mbnl1^−/− leukemia cells demonstrated longer leukemia-free survival (65 days) compared to mice secondarily transplanted with Mbnl1^+/+ leukemia cells (49 days) (Fig. 3c). In vitro studies of the CFU activity of Mbnl1^−/− MLL-AF9-transformed cells from bone marrow or spleen of primary or secondary recipients in serial replating assays showed no significant difference in colony numbers compared to Mbnl1^+/+ MLL-AF9-transformed cells. These results indicate that while the retrovirally expressed MLL-AF9 fusion gene can initiate leukemia in the absence of Mbnl1, disease development is significantly delayed.

**Fig. 3: MLL-AF9 leukemia is delayed in Mbnl1 knockout mice.**

Loss of Mbnl1 has a modest effect on normal murine hematopoiesis

In order to determine the role of Mbnl1 in normal murine hematopoiesis, we studied Mbnl1^−/− mice. At steady state, Mbnl1^−/− mice and Mbnl1^+/+ controls demonstrated comparable peripheral blood counts, bone marrow cellularity, and progenitor and stem cell counts. To test the role of Mbnl1 in stress hematopoiesis we injected Mbnl1^−/− KO and Mbnl1^+/+ wild type (WT) mice with one sublethal dose of 5-Fluorouracil (5-FU). No difference was observed regarding the time to recovery of RBCs, platelets, and WBCs from Mbnl1^−/− mice compared to controls (Fig. 4a). Next we tested the ability of bone marrow cells to repopulate lethally irradiated recipients as a function of stem cell activity in serial (non-competitive) transplantations. Analysis of bone marrow and peripheral blood post-transplantation did not reveal any significant difference in donor chimerism between primary recipients of Mbnl1^+/+ or Mbnl1^−/− bone marrow (Fig. 4b–d). Similarly, the distribution of cell lineages in the peripheral blood were identical between each group (Fig. 4e). Analysis of the bone marrow in secondary recipients also revealed no difference in donor chimerism levels between Mbnl1^+/+ and Mbnl1^−/− mice (Fig. 4c). Overall, these data demonstrate that the murine hematopoietic system functions normally under steady state conditions in the absence of Mbnl1.

To more rigorously compare Mbnl1 knock out and wild type hematopoietic function in vivo we performed competitive transplantation experiments. Lethally irradiated BoyJ recipient mice were transplanted with Mbnl1^−/− or Mbnl1^+/+ bone marrow cells (CD45.2) along with CD45.1 competitor bone marrow cells in a 1:1 ratio. Four weeks after transplantation the repopulation ability of transplanted cells was tested by peripheral blood flow cytometry for CD45.1 vs 45.2. Bone marrow analyses showed 73.8% and 30.3% CD45.2 donor chimerism in mice transplanted with Mbnl1^+/+ or with Mbnl1^−/− bone marrow cells, respectively (Fig. 4f). Periodic analysis of peripheral blood chimerism every 4 weeks showed a slight increase in donor chimerism in mice transplanted with Mbnl1^+/+ bone marrow cells while donor chimerism in mice transplanted with Mbnl1^−/− bone marrow cells remained stable (Fig. 4g). Analysis of peripheral blood lineages showed a delay in the ability of Mbnl1^−/− marrow to generate T-lymphocytes in competitive transplants while Gr1⁺ myeloid cells repopulated to levels comparable to Mbnl1^+/+ (Fig. 4h). These data suggest a slight disadvantage of Mbnl1^−/− cells under stress conditions of competitive transplant, with a specific deficiency in the ability of Mbnl1^−/− marrow to generate T-lymphocytes during competitive transplantation. To determine the etiology of this observation, we characterized the HSC compartment of Mbnl1^−/− mice and found that Mbnl1^−/− mice had a decreased proportion of Lin^-Sca1⁺Kit⁺-SLAM+(CD41-CD48-CD150+) HSCs compared to WT mice (Fig. 4i, j). Despite this, these mice at steady state exhibit no major hematopoietic deficits as evidenced by these experiments, suggesting that Mbnl1 loss is tolerated in normal hematopoiesis.

MBNL1-regulated alternative splicing is active in leukemic cells

One of the best known and explored functions of MBNL family proteins is alternative splicing of target mRNAs^{7,13,39,40,41}. We sought to identify whether canonical MBNL1 targets exhibit differential patterns of isoform usage across leukemia cells with differing degrees of MBNL1 expression. We selected the genes ATP2A1 and CD47, which have been shown to be regulated by MBNL1 during pluripotent stem cell differentiation⁴¹, as well as INF2, which is misspliced due to MBNL1 sequestration in the trinucleotide repeat disorder Fuchs endothelial corneal dystrophy⁴². In comparing the isoform expression profiles of these genes between MLL-wildtype and MLL-rearranged leukemias, we identified shifts in isoform utilization in MLL-rearranged leukemia cell lines which had high MBNL1 expression (Fig. 5a). Furthermore, MBNL1 knockdown in MLL-rearranged cell lines resulted in a shift in mRNA isoform expression resembling that of MBNL1-low cell lines (Fig. 5b)⁴¹. Pharmacologic inhibition of MBNL1 with Compound 1 as described above resulted in similar changes in alternative splicing of MBNL1 target genes (Fig. 5c). Intriguingly, these results suggest that at least some targets of MBNL1 are spliced in a tissue-agnostic manner, and that patterns of isoform expression associated with high MBNL1 expression are reversed upon MBNL1 knockdown in leukemia cells. These data provide further evidence for on-target activity of our MBNL1 inhibitor.

As an additional measure of MBNL1 activity, we investigated differential exon utilization in MBNL1 itself. Specifically, MBNL1 promotes exclusion of exon 5 in its own mature transcripts⁴³. We thus hypothesized that higher expression of MBNL1 will be associated with a greater proportion of MBNL1 transcripts with exon 5 excluded. Indeed, quantitative analysis revealed a higher ratio of exon 5 excluded transcripts in MLL-rearranged leukemias compared to non-MLL-rearranged leukemias (Supplementary Fig. 4A). Collectively, these data show that at least some putative targets of MBNL1 are consistent across different cell types, and that high MBNL1 expression correlates with increased alternative splicing of MBNL1 in MLL-rearranged leukemia.

MBNL1 mediates intron retention of genes differentially spliced in MLL-rearranged leukemia

To identify targets of MBNL1 specifically in MLL-rearranged leukemias, we performed RNA-Seq in two MLL-rearranged cell lines (MOLM13, MV4;11) with knockdown of MBNL1 and compared these results to those from the Leucegene consortium dataset of MLL-rearranged patient AML bone marrow samples⁴⁴. For these analyses, we compared patient samples with MLL oncofusions to cytogenetically normal (CN) AML patients, and non-targeting shRNA controls to MBNL1 knockdown (NT). Similar to other AML datasets, we find that MBNL1 is most highly induced in MLL-rearranged AMLs in RNA-seq derived from the Leucegene cohort and comparable sorted healthy control hematopoietic progenitors (Fig. 6a).

**Fig. 6: Partial reversal of impaired intron retention in MLL-rearranged cells by MBNL1 knockdown.**

Notwithstanding the disparate experimental setups of primary patient samples versus knockdown in a cell line, we hypothesized that the major impact of MBNL1 might be on alternative splicing of transcripts, given its well defined role in splicing regulation. We applied a recently developed method for splicing event and intron-retention analysis called MultiPath-PSI (AltAnalyze) to the patient and MBNL1 knockdown cell line data^45,46. Breakdown of alternative splicing and promoter events in these datasets by event-type finds that MLL-rearranged leukemias predominantly exhibit exclusion of retained introns when compared to CN-AML (Fig. 6b, top). We observed a similar difference in MOLM13 cells between MBNL1 knockdown and control, where loss of MBNL1 was predominantly associated with increased intron retention and a decrease in cassette exon inclusion (Fig. 6b, bottom). Relative to well-defined AML splicing-factor mutations and oncofusions in Leucegene, this intron-retention exclusion profile was most dominant in MLL-rearranged leukemias and to a lesser extent in core binding factor rearrangements (RUNX1, CBFB-MYH11) (Supplementary Fig. 5A) Visual inspection of AS events in MBNL1 knockdown using IGV readily confirmed these bioinformatics predictions (Fig. 6c). Comparison of splicing changes occurring with MBNL1 knockdown to AS events occurring in the MLL-rearranged patient cohort identifies a common core set of mutually regulated events. Intersection of these in vivo and in vitro comparisons finds that 89% of shared AS events are negatively concordant (e.g., oppositive pattern of exon/intron inclusion) between MLL-rearranged patient samples and in vitro MBNL1 knockdown, namely that specific alternative features retained in MLL-rearranged patient data were excluded in the MBNL1 knockdown condition, or vice versa. Multiple short hairpins against MBNL1 exhibited a high degree of concordance (>96%) in AS events across different cell lines (Fig. 6d, e; Supplementary Data 1). Manual inspection of these splicing events verified that MBNL1 knockdown rescues MLL fusion-associated splicing and intron retention events (Supplementary Fig. 6A, B). These data suggest that MBNL1 loss partially accounts for changes in specific AS events which occur in MLL-rearranged leukemias. Given that the number of in vivo and in vitro overlapping splicing events was relatively low, we more broadly examined concordance of MBNL1 knockdown AS events among major genetically/cytogenetically defined AML subtypes, including nearly 500 splicing factor knockdowns in K562 or HepG2 cells (ENCODE; Encyclopedia of DNA Elements) and normal hematopoetic cell types. Among these comparisons, MLL-rearranged AML proved to be the most highly anti-concordant to MBNL1 knockdown, with non-MLL rearanged MBNL1 knockdown (in K562 cells) among the most concordant (Fig. 6f; Supplementary Data 2). While shRNAs for other RNA-binding proteins (RBPs) had concordant AS with MBNL1, suggesting they regulate common targets or are regulated downstream of MBNL1, binding sites for MBNL1 were the most enriched among these for MBNL1 knockdown AS events, similar to that of MLL-rearranged splicing events (Fig. 6g, Supplementary Fig. 5B).

We subsequently examined the concordant AS decisions, and noted that they were highly enriched in regulators of small GTPase mediated signal transduction (RHOC, RHPN1, DLG4, ARHGEF40, ARHGEF1, DENND4B, ARHGAP17, ARAP1, DNM2), regulators of Notch signaling (NCOR2, NUMB, AA2) and genes mediating membrane trafficking and vesicle-mediated transport (BICD2, REPS1, SCARB1, SEC16A, DENND4B, AAK1, AP1G2, EXOC1, EXOC7, GOLGA2, DNM2) (Fig. 6h). Furthermore, we consistently identified missplicing (specifically intron retention) of key genes implicated in the pathogenesis of MLL-rearranged leukemia, namely SETD1A and DOT1L (Fig. 6h). Both DOT1L and SETD1A are histone methyltransferases known to perform essential functions in the MLL leukemogenic program^47,48,49. We hypothesized that of the alternatively spliced targets we identified, disruptions of genes involved in the pathogenesis of MLL-rearranged leukemia^47,50 such as DOT1L and SETD1A may explain the growth inhibition that we observed. We first experimentally validated and characterized the splicing predictions identified by our analysis. Indeed, RT-PCR with primers spanning the predicted splice junctions confirmed the predicted AS events from our RNA-seq analysis (Fig. 7a). We also performed RNA-immunoprecipitation using MBNL1-specific antibodies, and found substantial enrichment of DOT1L and SETD1A transcripts in precipitated RNA compared to control IgG (Fig. 7b), suggesting that MBNL1 interacts directly with the differentially spliced transcripts that we identified. These splicing changes lead to protein-level effects, with either decreases in total protein or shifts in protein isoforms of DOT1L and SETD1A after MBNL1 knockdown (Fig. 7c) likely due predominantly to nonsense-mediated decay arising from the incorporation of premature termination codons within retained introns. We subsequently performed RNA-seq on MBNL1 knockdown MOLM13 cells at a later time point, reasoning that splicing changes and alterations in histone methyltransferases may not immediately be reflected in gene expression if assayed at too early a timepoint. We managed to collect sufficient RNA for analysis at 12 days after knockdown, and found a marked increase in the number of differentially expressed genes when compared to the 4 day timepoint (Fig. 7d; Supplementary Data 3). Through gene set enrichment analysis (GSEA)⁵¹ of our day 12 knockdown signature, we found significant corresponding bidirectional enrichment for gene sets associated with perturbation or disruption of central mediators of the MLL leukemia program, specifically HOXA9⁵² and glycogen synthase kinase 3, previously shown to be required for MLL leukemogenesis by Wang et al.^53,54 (Fig. 7e). Together, these results suggest that loss of MBNL1 in MLL rearranged leukemia results in a state analogous to disruption of essential components of the MLL leukemia program, culminating in leukemia cell death.

**Fig. 7: MBNL1 loss perturbs essential MLL-rearranged leukemia genes through missplicing.**

Discussion

Our findings described above demonstrate that MBNL1 is essential for MLL-rearranged leukemia cell growth, yet only modestly so for normal hematopoiesis. We also demonstrate using novel bioinformatic analyses that MLL-rearranged leukemias exhibit a unique pattern of mRNA isoform utilization that is partially reversed upon knockdown of MBNL1, suggesting that MBNL1-mediated alternative mRNA splicing patterns contribute to the pathogenesis of MLL-rearranged leukemias.

MBNL1 is well known to regulate RNA alternative splicing, localization, and decay^7,8,9,10,11, though an understanding of its role in disease pathogenesis has been largely limited to DM1 and Fuchs corneal endothelial dystrophy^42,55. Recently, MBNL proteins have been reported to control the pluripotency of embryonic stem cells and fetal terminal erythropoiesis as well^13,14, implicating their activity to some extent in the hematopoietic system. In examining results of gene expression profiling of MLL leukemias, we identified MBNL1 as one of the most consistently overexpressed genes in this family of leukemia regardless of lineage, even more so than the HOXA cluster genes. This may be due to the fact that even within MLL-rearranged leukemias HOXA gene expression can be highly variable, especially in pre-B ALL^6,56,57. Because we sought commonalities in gene overexpression across both myeloblastic and lymphoblastic leukemias, this may explain why the HOXA cluster genes were not consistently overexpressed in every dataset we examined.

The results of our RNA-seq and splicing analyses suggest that a major function of MBNL1 in MLL-rearranged leukemia is through alternative splicing, and a number of alternatively spliced genes identified using our approach have been implicated in leukemogenesis, including a subset of epigenetic regulators such as the H3K79 methyltransferase DOT1L and the SET1 histone methyltransferase complex member and cyclin K regulator SETD1A. A frequent splicing outcome following MBNL1 knockdown was intron retention, and MBNL1 knockdown appears generally to reverse intron exclusion. Our findings suggest that MLL-fusion proteins, via MBNL1 overexpression, promote the expression of protein coding genes typically suppressed through intron retention-introduced premature termination codons. The negative impacts of MBNL1 knockdown on cell growth are likely a net effect of multiple transcripts (and the subsequent proteins) being affected, rather than solely arising from alternative splicing of the products of a single gene. Ultimately, it remains challenging to quantify the exact extent to which MBNL1 or other splicing factors mediate specific oncogenic splicing programs in vivo, due to a lack of controlled model systems to quantify such effects. In our analysis, we compared MLL-rearranged patient samples to CN-AML as a control, however even within this comparison there are likely additional splicing differences attributable in part to phenomena such as lineage skewing⁵⁸, co-occurrence of spliceosome mutations within the patient cohort analyzed above⁴⁴, or other yet-unidentified MLL fusion-specific transcriptional/splicing programs, hence isolation of a core splicing factor-associated program in vitro will only remain an approximation of molecular programs found in patients. Despite this, we demonstrate a high degree of splicing discordance between MBNL1 loss and MLL fusion-associated patient splicing, indicating a high specificity of our analysis for MBNL1-mediated splicing events.

All three members of the MBNL family regulate alternative splicing during development. Mbnl1^−/− mice display splicing defects in heart and skeletal muscle yet do not present clinical features of DM1. Notably, Mbnl2 was found to compensate for Mbnl1 in murine tissues⁵⁹. We speculate that a similar phenomenon might explain the eventual development of leukemia in our Mbnl1^−/− mice despite the growth inhibition in our knockdown studies in human cells. In both Mbnl1^+/+ and Mbnl1^−/− states Mbnl2 and Mbnl3 are stably expressed in mouse leukemia cells, however neither analogue was meaningfully expressed in the human leukemia lines assayed (Supplementary Fig. 7A–B). Therefore, one possible explanation for the eventual development of leukemia in our Mbnl1^−/− murine model is that Mbnl2 compensates for the absence of Mbnl1, but it is unclear if this compensatory mechanism would necessarily behave similarly in human cells. Alternately, it is plausible that MBNL1 loss in a transformed cell (i.e., genetic knockdown in leukemia cell lines) may be more deleterious than de novo transformation of an MBNL1-deficient cell, as occurs in the mouse retroviral leukemia model. We hypothesize that transformation of Mbnl1^−/− cells could conceivably engage alternate oncogenic pathways which eventually allow leukemia cell survival, though this issue of MBNL1 requirement for MLL leukemia initiation versus propagation requires further study.

Given the poor prognosis of patients with MLL-rearranged acute leukemia, there remains an urgent need for better therapeutic approaches in this subgroup of patients. Our data suggests that targeting MBNL1 may be a valid therapeutic avenue in the treatment of MLL-rearranged leukemia. As a proof of concept, we demonstrate that a small-molecule inhibitor rationally designed against MBNL1 can preferentially kill MLL-rearranged leukemia cells while sparing normal CD34⁺ hematopoietic stem/progenitor cells. An alternative therapeutic approach may involve targeting elements of the MBNL1 transcript itself using therapeutic RNA inhibition specifically targeted at hematopoietic or leukemic cells. Specifically, our data suggest that human MLL-rearranged leukemia cells have increased expression of MBNL1 transcripts that exclude exon 5 which influences nuclear vs cytoplasmic localization of MBNL1^14,43. We hypothesize that the role of MBNL1 in facilitating productive splicing of the MLL-rearranged oncogenic program may in part be mediated by exon 5 exclusion. Therapeutics which influence exon utilization (such as antisense oligonucleotides) may thus represent an alternate means of disrupting the function of MBNL1. However, the specific role of the exclusion transcript and the associated cellular localization are not fully understood and require further study.

In conclusion, we provide evidence supporting a model in which MBNL1 overexpression mediated by the MLL-fusion protein promotes leukemogenesis via an altered splicing profile (primarily changes in intron retention) of MBNL1 targets. We demonstrate that MBNL1 is an important regulator of alternative splicing events preferentially expressed in MLL-rearranged leukemia and which participate in the MLL-rearranged oncogenic program. Our data shows the effect of MBNL1 at the mRNA and protein level, and suggests that MBNL1 plays a key role in the pathogenesis of MLL-rearranged leukemia by stabilizing the transcripts of multiple leukemogenic genes including DOT1L and SETD1A; this in turn supports transcriptional activation of downstream targets of the MLL-fusion protein, including activation of MBNL1, creating a positive feedback loop (Fig. 8). We also show that a specific, albeit low potency, inhibitor of MBNL1 preferentially affects MLL-rearranged leukemia cells. Given recent discoveries supporting the concept of selective RNA binding protein essentiality in AML⁶⁰, our work provides further evidence that this is a valid new class of targets in this poor-prognosis class of diseases. Furthermore, our work serves as proof of principle for development of anti-MBNL1 therapies. Additional research is ongoing to further elucidate the mechanisms underlying MBNL1 dependence in MLL-rearranged leukemia, as well as to further optimize candidate small-molecule inhibitors.

**Fig. 8: Working hypothesis for the role of MBNL1 in MLL-rearranged leukemia.**

Methods

Cell lines and primary patient cells/data

Human leukemia cell lines were maintained in Iscove’s modified Dulbecco medium (IMDM) or Roswell Park Memorial Institute (RPMI) 1640 medium supplemented with 10% fetal bovine serum (FBS), 1% penicillin, and 1% streptomycin.

Fully deidentified primary patient cells were obtained from the Cincinnati Children’s Hospital Medical Center Biorepository. Patient identities have been protected. PDX models were generated using residual diagnostic specimens according to an IRB approved protocol (#2008-0021) following proper informed consent. Cells from patient samples were transplanted into busulfan-conditioned NOD/LtSz-SCID interleukin-2(IL2)RG−/− SGM3 (NSGS) (Jackson Laboratories, stock no. 013062) mice. By the time the mice displayed signs of leukemia, the only human cells that remained in the mice were leukemic cells (MLL-rearrangement was confirmed with FISH). De-identified PDX spleen samples taken from NSGS mice (Jackson Laboratories, stock no. 013062) were used for the ex vivo knockdown experiments described below. Cells were cultured in IMDM supplemented with 20% FBS and 10 ng/ml human cytokines including SCF, FLT3-Ligand, Thrombopoietin, IL-3, and IL-6.

MLL-AF9 Tet-off human CD34+ cells were a kind gift from Dr. James Mulloy, and were generated as follows. Umbilical cord blood (UCB) was obtained from the Translational Trial Development and Support Laboratory (TTDSL) of CCHMC. UCB units are collected and distributed by the TTDSL under an IRB-approved protocol, and originate from discarded umbilical cords and are thus completely anonymized, rendering them exempt from human subjects research. CD34+ cells were isolated from UCB using the EasySep CD34+ isolation kit (StemCell Technologies). CD34+ cells were pre-stimulated in IMDM/20%FBS containing 100 ng/mL SCF, TPO, Flt3-L, and IL-6 and 20 ng/mL IL-3 for 2 days before transduction. Transduction was carried out using spinoculation onto Retronectin (Takara Bio) coated plates along with 4 µg/mL polybrene. Cells were trasduced with both the pSIN-TREtight-dsRED-MLL/AF9³⁵ lentivirus and the MSCV-GFP-IRES-tTA³⁴ retrovirus. After transduction, cells were maintained in IMDM/20% FBS with 10 ng/mL of each cytokine. A pure population of dsRED+GFP+ cells were selected over several weeks of culture. To repress expression of the MLL fusion, cells were treated with 1 µg/mL doxycycline.

Cell lines were periodically validated by STR genotyping through Genetica Cell Line Testing (LabCorp). Cells were tested and were negative for mycoplasma contamination. None of the cell lines utilized in this study are recognized by the ICLAC as being commonly misidentified.

RNA-Seq data for primary patient AML and ALL samples were obtained from the St. Jude Cloud (originating publications/datasets as cited in the “Results” section), and from www.vizome.org/aml as indicated.

Mouse experiments

All animals used for this study were 6–12-weeks old. All animal experiments were carried out in accordance with the guidelines of the Institutional Animal Care and Use Committee (IACUC). C57BL/6 mice were used as donors for transplantation experiments using Mbnl1^−/− or Mbnl1^+/+ cells. For studies of normal murine hematopoiesis, 1 × 10⁶ CD45.2 Mbnl1^−/− or Mbnl1^+/+ bone marrow donor cells were transplanted with 1 × 10⁶ CD45.1 competitor cells (for competitive transplantation, 1:1 ratio) or without competitor cells (non-competitive transplantation) into lethally irradiated BoyJ recipient mice (RRID: IMSR_JAX:002014). Four or eight weeks after transplantation, bone marrow of recipients was analyzed for donor chimerism. Mice were assessed for signs of leukemia, and when distressed, were sacrificed and tested for leukocytosis, anemia, thrombocytopenia and splenomegaly. For normal hematopoiesis experiments, peripheral blood of recipients was examined every 4 weeks and bone marrow was tested at the end point of the experiment for the presence of donor cells by flow cytometry. For studies of time-to-leukemia in Mbnl1 knockout mice, BoyJ recipient mice were conditioned by sub-lethal irradiation and i.v. injected with 2 × 10⁵ transduced donor cells. For xenograft experiments with MLL-rearranged cell lines, immunocompromised NOD/LtSz-SCID interleukin-2(IL2)RG−/− (NSG) (Jackson Laboratories, stock no. 005557) recipient mice were treated with busulfan (Sigma) 30 µg/mg intraperitoneally and transplanted with 2 × 10⁵ human cells 24 h later. For xenograft experiments with MLL-rearranged primary patient cells, immunocompromised NOD/LtSz-SCID interleukin-2(IL2)RG−/− SGM3 (NSGS) (Jackson Laboratories, stock no. 013062) recipient mice were conditioned with busulfan and transplanted with 2–7.5 × 10⁵ human cells 24 h later. In xenograft experiments bone marrow samples were collected four weeks after transplantation as well as when signs of leukemia were present; aspirates were analyzed via flow cytometry for the presence of human CD45⁺ cells and the presence of shRNA-transduced CD45⁺ and Venus-positive cells

Retroviral and lentiviral transductions

Retroviral and lentiviral supernatants were generated by transfection of HEK293T cells using the CaPO₄ method or FuGENE 6 reagent (Promega) according to the manufacturer’s recommendations. Mouse bone marrow cells were isolated by crushing ischial bones, femurs and tibias. Cells were then lineage-depleted using the Lineage Cell Depletion kit (Miltenyi Biotec) following magnetic separation by using an AutoMACS Pro Separator (Miltenyi Biotec). Lineage-negative cells were then pre-stimulated with 100 ng/ml cytokines (SCF, G-CSF and Thrombopoietin) (Peprotech) overnight and transduced with retroviral MLL-AF9 constructs using spinoculation on retronectin-coated plates.

The lentiviral MBNL1 shRNA pLKO.1-Puro plasmids (TRCN0000063963, TRCN0000063964, TRCN0000063965, TRCN0000063966, and TRCN0000063967) were purchased from Millipore Sigma. Human cells were incubated with a single dose of lentiviral supernatant overnight. Cells transduced with constructs granting puromycin resistance were selected in 0.5–5 µg/ml of Puromycin for 72 h. Cells transduced with constructs containing a fluorescent marker (GFP, YFP or Venus) were isolated on day 4–5 after transduction by sorting using a MoFlo XDP (Beckman Coulter), FACSAria (BD Biosciences), or a Sony SH800S (Sony Biotechnology.) MSCV MLL-AF9 GFP was a kind gift from Dr. Gang Huang.

Flow cytometry

For murine peripheral blood flow cytometry analysis, peripheral blood was collected by retro-orbital bleeding and incubated with surface antibodies (eBioscience) in staining buffer (phosphate-buffered saline (PBS) supplemented with 0.5% FBS). Peripheral blood cell suspensions were treated with Pharm Lyse Lysing Buffer (BD Biosciences) and washed twice with PBS. For apoptosis assays, cells were incubated with allophycocyanin-conjugated Annexin V (BD Bioscience) for 15 min at RT in 1X Annexin V Binding Buffer (BD Bioscience) following staining with 7-aminoactinomycin (eBioscience). Data were acquired on a FACSCanto I and results were analyzed using FlowJo Version 10 (FlowJo). The list of antibodies used for flow cytometry analysis of mouse and human cells is indexed in Supplementary Data 4.

Colony-forming unit assays

Mouse bone marrow cells were plated in methylcellulose-containing media (StemCell Technologies, Methocult M3434) supplemented with 10 ng/ml of granulocyte-macrophage colony-stimulating factor (Peprotech). After 7–8 days of culture, colonies were counted and re-plated for 3–5 rounds. Human cells were cultured in methylcellulose-containing media (StemCell Technologies, H4434). Colonies were scored 14 days after plating. The Nikon Eclipse Ti-U scope was used for images of colonies and automatic counting was performed using Nikon Elements software.

RT- and quantitative RT-PCR

Total RNA was extracted from human Puromycin-selected or sorted Venus-positive cells using the RNeasy Mini kit (Qiagen). RNA was reversed transcribed into cDNA using iScript Advanced cDNA Synthesis kit (Bio-Rad Laboratories). RT-PCR reactions were carried out in an Eppendorf PCR Cycler using MyTaq^TM HS Red Mix (Bioline) according to the manufacturer recommendations. The amplified reaction products were separated on a agarose gel (ranging from 1 to 3.5%). The BioChemi System (UVP Bioimaging system) was used for visualization and analysis (Image Lab 6.0 used for band quantification). For quantitative RT-PCR 5–10 ng of cDNA was analyzed using iTaq Universal SYBR Green Supermix and iTaq Universal Probes Supermix (Bio-Rad) in a StepOnePlus Real-Time PCR machine (Applied Biosystems). Primers for RT-PCR are detailed in Supplementary Data 5.

RNA-Immunoprecipitation

RNA-Immunoprecipitation was performed using the Magna RIP kit (Millipore). 2.0 × 10⁷ cells were used per immunoprecipitation reaction. Five micrograms of either mouse anti-IgG (Millipore, CS200621) or anti-MBNL1 (Millipore, clone 4A8) was used. After RNA-immunoprecipitation, RNA was extracted and analyzed via qRT-PCR through the process described in the “RT- and Quantitative RT-PCR” section, with the exception that the qRT-PCR was run using Taqman Probes (Thermo Fisher Scientific, Hs_00986924 for SETD1A and Hs_05017433 for DOT1L) instead of SYBR Green.

Western blotting

The primary antibodies used were anti-MLL1 (Bethyl, A300-086A, RRID: AB_242510), anti-MBNL1 (Millipore Sigma, clone 4A8, RRID: AB_10808499), anti-DOT1L (Cell Signalling, D1W4Z, RRID:AB_2799889), anti-SETD1A (Cell Signalling, D3V9S, RRID:AB_2799614), anti-Actin (Cell Signalling Technology, 13E5, RRID: AB_2223172), anti-Lamin B1 (Cell Signaling Technology, D4Q4Z, RRID: AB_2650517) and anti- β-tubulin (Cell Signaling Technology, 9F3, RRID: AB_823664). Whole cell lysates were isolated using RIPA buffer (Sigma) while nuclear extracts were obtained using the NE-PER kit (Thermo Scientific) according to manufacturer’s instructions, and the amount of protein was determined by the BCA Protein Assay Kit (Thermo Scientific). Ten µg of protein was separated by SDS-PAGE on a 4–20% gradient gel (Bio-Rad). After transfer to PVDF membranes, blots were blocked with Odyssey® Blocking Buffer TBS (LI-COR) for one hour and incubated with primary antibodies overnight. After washing, blots were treated with appropriate secondary IRDye 680RD goat anti-mouse (LI-COR) and IRDye 800CW goat anti-rabbit (LI-COR) antibodies at a dilution of 1:10,000 for one hour. Images were obtained using the Odyssey CLx Infrared Imaging System (LI-COR).

Inhibitor assay

0.5 × 10⁵ cells/ml were plated in a 96-well plate and incubated with the inhibitor at a concentration of 250 µM, 500 µM, or vehicle (DMSO). At various time points after incubation cells were stained with Annexin V and 7-AAD and analyzed by flow cytometry; additionally, viable cells were counted using Trypan Blue.

ChIP-seq and microarray reanalysis

For Fig. 1a, pre-computed microarray gene expression signatures for MLL-rearranged versus WT leukemias were obtained from the following sources: Ross et al., Blood 2004 Supplementary Table 10⁴, Mullighan et al. Leukemia 2007 Suppl Table 5²², Zangrando et al. BMC Med Genomics 2009 Suppl Table 2²¹ and Stam et al. Blood 2010 Suppl Table 5⁶. Probe IDs were reconciled with gene symbols, and intersections were determined and visualized with http://bioinformatics.psb.ugent.be/webtools/Venn/.

For Fig. 1c, previously analyzed bigWig/bedgraph files were downloaded from the Gene Expression Omnibus using the listed accession numbers (GSE95511 for ML-2 data, GSE79899 for MV4;11 and THP-1 data, GSE38403 for RS4;11 data, and GSE38338 for SEM data) and visualized with the UCSC Genome Browser, assembly hg19. For consistency, data for RS4;11 and SEM were converted from their originally mapped hg18 to hg19 using the liftOver tool from the UCSC Genome Browser Utilities.

Statistics

All means were compared using two-tailed t-tests unless specifically indicated otherwise. For survival analyses, log-rank tests were used to compare survival curves. The statistics used for the RNA sequencing analyses are described in the section below (“RNA sequencing and analysis”). Graphpad Prism 8 was used to perform statistical tests and create graphs. Select figures created with BioRender.com.

RNA sequencing and analysis

RNA sequencing was performed on total RNA obtained from MOLM13 or MV411 cell lines following transduction with either MBNL1 sh64 (n = 3 MOLM13, n = 3 MV411), sh65 (n = 4 MOLM13, n = 4 MV411) or shNT control (n = 3 MOLM13, n = 4 MV411) at a depth of >40 million paired-end stranded reads using the Illumina HiSeq 2500 (GSE123441), following library preparation with the TruSeq RNA Library Prep Kit (Illumina), similar to that of the Leucegene RNA-Seq dataset (GSE67040). A longer 12-day MBNL1 knockdown with independent shNT controls (MOLM13) was also performed as biological triplicates, processed with the same protocol on an Illumina NovaSeq platform. AML FASTQ files for MLL (n = 27) and CN AML patients (n = 29) were downloaded from the GEO database as previously described⁴⁴. All FASTQ files were aligned to the reference human genome (GRCh37/hg19) using the latest version of STAR⁶¹. Exon-exon and exon-intron spanning reads were determined from the software AltAnalyze (version 2.1.1) using the Ensembl-72 human database, along with splicing event calculation and annotation with the MultiPath-PSI algorithm (see: http://altanalyze.readthedocs.io/en/latest/Algorithms for algorithm details and benchmarking). For comparative splicing analyses, >50% of samples for each splicing event were required to have detected PSI value, consistent between the patient dataset and transduced cell line analyses. As statistical thresholds, we used a two-tailed empirical Bayes moderated (eBayes) t-test with p ≤ 0.01 for shRNA analyses and delta PSI > 0.1. Breakdown of splicing event categories is provided through the MultiPath-PSI software and associated heatmap visualization through AltAnalyze. For the MLL patient samples versus CN, an eBayes t-test was also performed (p ≤ 0.01) and delta PSI > 0.1 was used for differential splicing analysis. Only unique junction-cluster ID results were reported. Relative PSI differences were calculated separately for patient dataset and transduced cell line samples for joint visualization. Gene expression analyses were similarly performed in AltAnalyze from the input STAR BAM files, using the same p-value thresholds and 1.5 fold change cutoff, with gene-level RPKM quantification. ENCODE RNA binding protein knockdown and control hematopoetic cell type splicing comparison results were used from a prior study as previously described⁴⁶. RNA recognition element (RRE) enrichment analysis was performed on alternatively spliced exons and introns (exons with 500nt flanking intron sequence bins) using the software HOMER⁶² from a large database of RRE motif models in the form of position frequency matrices (PFMs) taken from the CisBP-RNA database⁶³. Evaluation of spilcing concordance was performed using a custom Python script. Pathway enrichment analysis was performed with ToppGene⁶⁴. GSEAPreranked⁵¹ was performed on differentially expressed genes as determined by AltAnalyze.

Reporting summary

Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability

The RNA-seq data (MOLM13 and MV4;11 cells with shNT versus multiple shMBNL1 knockdown conditions) have been deposited to the NCBI Gene Expression Omnibus (GEO) under accession number GSE123441.

The RNA-seq data for pediatric leukemia samples used for analysis in this study were obtained from the hematologic malignancies patient cohort of the St. Jude Cloud (https://pecan.stjude.cloud), a publicly accessible pediatric genomic data resource requiring approval for controlled data access.

The RNA-seq expression data from the ‘BeatAML’ dataset was obtained from www.vizome.org/aml, a publicly accessible AML genomic data resource, using the gene expression viewer stratified by WHO fusion category. Original data used to generate Fig. 6b, d, e, f, h are included as Supplementary Tables 1 and 2. The original data to generate Fig. 7d is included as Supplementary Table 3. The original gels and blots for Figs. 1d, 2a, 5, 7a and c are included as Supplementary Data. All the other data supporting the findings of this study are available within the article and its supplementary information files and from the corresponding author upon reasonable request.

Code availability

AltAnalyze is an open source software package, and freely available for download at www.altanalyze.org

Change history

07 July 2020
An amendment to this paper has been published and can be accessed via a link at the top of the paper.

References

Ziemin-van der Poel, S. et al. Identification of a gene, MLL, that spans the breakpoint in 11q23 translocations associated with human leukemias. Proc. Natl Acad. Sci. USA 88, 10735–10739 (1991).
Article ADS CAS PubMed PubMed Central Google Scholar
Chen, C. S. et al. The chromosome 4q21 gene (AF-4/FEL) is widely expressed in normal tissues and shows breakpoint diversity in t(4;11)(q21;q23) acute leukemia. Blood 82, 1080–1085 (1993).
Article CAS PubMed Google Scholar
Chen, W. et al. Malignant transformation initiated by Mll-AF9: gene dosage and critical target cells. Cancer Cell 13, 432–440 (2008).
Article CAS PubMed PubMed Central Google Scholar
Ross, M. E. et al. Gene expression profiling of pediatric acute myelogenous leukemia. Blood 104, 3679–3687 (2004).
Article CAS PubMed Google Scholar
Armstrong, S. A. et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat. Genet. 30, 41–47 (2002).
Article CAS PubMed Google Scholar
Stam, R. W. et al. Gene expression profiling-based dissection of MLL translocated and MLL germline acute lymphoblastic leukemia in infants. Blood 115, 2835–2844 (2010).
Article CAS PubMed Google Scholar
Ho, T. H. et al. Muscleblind proteins regulate alternative splicing. EMBO J. 23, 3103–3112 (2004).
Article CAS PubMed PubMed Central Google Scholar
Terenzi, F. & Ladd, A. N. Conserved developmental alternative splicing of muscleblind-like (MBNL) transcripts regulates MBNL localization and activity. RNA Biol. 7, 43–55 (2010).
Article CAS PubMed Google Scholar
Wang, E. T. C. et al. regulation of pre-mRNA splicing and mRNA localization by muscleblind proteins. Cell 150, 710–724 (2012).
Article CAS PubMed PubMed Central Google Scholar
Batra, R. et al. Loss of MBNL leads to disruption of developmentally regulated alternative polyadenylation in RNA-mediated disease. Mol. Cell 56, 311–322 (2014).
Article CAS PubMed PubMed Central Google Scholar
Masuda, A. et al. CUGBP1 and MBNL1 preferentially bind to 3’ UTRs and facilitate mRNA decay. Sci. Rep. 2, 209 (2012).
Article PubMed PubMed Central CAS Google Scholar
Konieczny, P., Stepniak-Konieczna, E. & Sobczak, K. MBNL proteins and their target RNAs, interaction and splicing regulation. Nucleic Acids Res. 42, 10873–10887 (2014).
Article CAS PubMed PubMed Central Google Scholar
Han, H. et al. MBNL proteins repress ES-cell-specific alternative splicing and reprogramming. Nature 498, 241–245 (2013).
Article ADS CAS PubMed PubMed Central Google Scholar
Cheng, A. W. et al. Muscleblind-like 1 (Mbnl1) regulates pre-mRNA alternative splicing during terminal erythropoiesis. Blood 124, 598–610 (2014).
Article CAS PubMed PubMed Central Google Scholar
Adamia, S. et al. A genome-wide aberrant RNA splicing in patients with acute myeloid leukemia identifies novel potential disease markers and therapeutic targets. Clin. Cancer Res. 20, 1135–1145 (2014).
Article CAS PubMed Google Scholar
Adamia, S. et al. NOTCH2 and FLT3 gene mis-splicings are common events in patients with acute myeloid leukemia (AML): new potential targets in AML. Blood 123, 2816–2825 (2014).
Article CAS PubMed PubMed Central Google Scholar
Mohamed, A. M. et al. How mRNA is misspliced in acute myelogenous leukemia (AML). Oncotarget 5, 9534–9545 (2014).
Mohamed, A. M. et al. Oncogene- and drug resistance-associated alternative exon usage in acute myeloid leukemia (AML). Oncotarget 7, 2889–2909 (2016).
Article PubMed Google Scholar
Sun, L. et al. Expression of aberrantly spliced oncogenic ikaros isoforms in childhood acute lymphoblastic leukemia. J. Clin. Oncol. 17, 3753–3766 (1999).
Article CAS PubMed Google Scholar
Wilkinson, A. C. et al. RUNX1 is a key target in t(4;11) leukemias that contributes to gene activation through an AF4-MLL complex interaction. Cell Rep. 3, 116–127 (2013).
Article CAS PubMed PubMed Central Google Scholar
Zangrando, A., Dell’orto, M. C., Te Kronnie, G. & Basso, G. MLL rearrangements in pediatric acute lymphoblastic and myeloblastic leukemias: MLL specific and lineage specific signatures. BMC Med Genomics 2, 36 (2009).
Article PubMed PubMed Central Google Scholar
Mullighan, C. G. et al. Pediatric acute myeloid leukemia with NPM1 mutations is characterized by a gene expression profile with dysregulated HOX gene expression distinct from MLL-rearranged leukemias. Leukemia 21, 2000–2009 (2007).
Article CAS PubMed Google Scholar
Tyner, J. W. et al. Functional genomic landscape of acute myeloid leukaemia. Nature 562, 526–531 (2018).
Article ADS CAS PubMed PubMed Central Google Scholar
Liu, Y. et al. The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nat. Genet. 49, 1211–1218 (2017).
CAS PubMed PubMed Central Google Scholar
Zhang, J. et al. Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. Nat. Genet. 48, 1481–1489 (2016).
Article CAS PubMed PubMed Central Google Scholar
Andersson, A. K. et al. The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias. Nat. Genet. 47, 330–337 (2015).
Article CAS PubMed PubMed Central Google Scholar
Faber, Z. J. et al. The genomic landscape of core-binding factor acute myeloid leukemias. Nat. Genet. 48, 1551–1556 (2016).
Article CAS PubMed PubMed Central Google Scholar
de Rooij, J. D. et al. Pediatric non-Down syndrome acute megakaryoblastic leukemia is characterized by distinct genomic subsets with varying outcomes. Nat. Genet. 49, 451–456 (2017).
Article PubMed PubMed Central CAS Google Scholar
Lin, S. et al. Instructive role of MLL-fusion proteins revealed by a model of t(4;11) Pro-B acute lymphoblastic leukemia. Cancer Cell 30, 737–749 (2016).
Article CAS PubMed Google Scholar
Prange, K. et al. MLL-AF9 and MLL-AF4 oncofusion proteins bind a distinct enhancer repertoire and target the RUNX1 program in 11q23 acute myeloid leukemia. Oncogene 36, 3346–3356 (2017).
Article CAS PubMed PubMed Central Google Scholar
Numata, A. et al. The basic helix-loop-helix transcription factor SHARP1 is an oncogenic driver in MLL-AF6 acute myelogenous leukemia. Nat. Commun. 9, 1–16 (2018).
Article CAS Google Scholar
Geng, H. et al. Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia. Cancer Discov. 2, 1004–1023 (2012).
Article CAS PubMed PubMed Central Google Scholar
Guenther, M. G. et al. Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia. Genes Dev. 22, 3403–3408 (2008).
Article CAS PubMed PubMed Central Google Scholar
Zhao, X. et al. Downregulation of RUNX1/CBFbeta by MLL fusion proteins enhances hematopoietic stem cell self-renewal. Blood 123, 1729–1738 (2014).
Article CAS PubMed PubMed Central Google Scholar
Zuber, J. et al. An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance. Genes Dev. 25, 1628–1640 (2011).
Article CAS PubMed PubMed Central Google Scholar
Wei, J. et al. Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia. Cancer Cell 13, 483–495 (2008).
Article CAS PubMed PubMed Central Google Scholar
Childs-Disney, J. L. et al. Induction and reversal of myotonic dystrophy type 1 pre-mRNA splicing defects by small molecules. Nat Commun 4, 2044, (2013).
Kanadia, R. N. et al. A muscleblind knockout model for myotonic dystrophy. Science 302, 1978–1980 (2003).
Article ADS CAS PubMed Google Scholar
Du, H. et al. Aberrant alternative splicing and extracellular matrix gene expression in mouse models of myotonic dystrophy. Nat. Struct. Mol. Biol. 17, 187–193 (2010).
Article CAS PubMed PubMed Central Google Scholar
Lin, X. et al. Failure of MBNL1-dependent post-natal splicing transitions in myotonic dystrophy. Hum. Mol. Genet. 15, 2087–2097 (2006).
Article CAS PubMed Google Scholar
Venables, J. P. et al. MBNL1 and RBFOX2 cooperate to establish a splicing programme involved in pluripotent stem cell differentiation. Nat. Commun. 4, 1–10 (2013).
Article CAS Google Scholar
Du, J. et al. RNA toxicity and missplicing in the common eye disease fuchs endothelial corneal dystrophy. J. Biol. Chem. 290, 5979–5990 (2015).
Article CAS PubMed PubMed Central Google Scholar
Gates, D. P., Coonrod, L. A. & Berglund, J. A. Autoregulated splicing of muscleblind-like 1 (MBNL1) Pre-mRNA. J. Biol. Chem. 286, 34224–34233 (2011).
Article CAS PubMed PubMed Central Google Scholar
Lavallee, V.-P. et al. The transcriptomic landscape and directed chemical interrogation of MLL-rearranged acute myeloid leukemias. Nat. Genet. 47, 1030–1037 (2015).
Article CAS PubMed Google Scholar
Fang, J. et al. TRAF6 Mediates Basal Activation of NF-kappaB Necessary for Hematopoietic Stem Cell Homeostasis. Cell Rep 22, 1250–1262 (2018)
Muench, D. E. et al. SKI controls MDS-associated chronic TGF-beta signaling, aberrant splicing, and stem cell fitness. Blood 132, e24–e34, (2018).
Hoshii, T. et al. A Non-catalytic function of SETD1A regulates cyclin K and the DNA damage response. Cell 172, 1007–1021 (2018).
Article CAS PubMed PubMed Central Google Scholar
Deshpande, A. J. et al. Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l. Blood 121, 2533–2541 (2013).
Article CAS PubMed PubMed Central Google Scholar
Bernt, K. M. et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 20, 66–78 (2011).
Article CAS PubMed PubMed Central Google Scholar
Winters, A. C. & Bernt, K. M. MLL-rearranged leukemias— an update on science and clinical approaches. Front. Pediatrics 5, 1–21 (2017).
Article Google Scholar
Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005).
ADS CAS PubMed PubMed Central Google Scholar
Faber, J. et al. HOXA9 is required for survival in human MLL-rearranged acute leukemias. Blood 113, 2375–2385 (2009).
Article CAS PubMed PubMed Central Google Scholar
Wang, Z. et al. GSK-3 promotes conditional association of CREB and its coactivators with MEIS1 to facilitate HOX-mediated transcription and oncogenesis. Cancer Cell 17, 597–608 (2010).
Article CAS PubMed PubMed Central Google Scholar
Wang, Z. et al. Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy. Nature 455, 1205–1209 (2008).
Article ADS CAS PubMed PubMed Central Google Scholar
Miller, J. W. et al. Recruitment of human muscleblind proteins to (CUG)(n) expansions associated with myotonic dystrophy. EMBO J. 19, 4439–4448 (2000).
Article CAS PubMed PubMed Central Google Scholar
Starkova, J. et al. HOX gene expression in phenotypic and genotypic subgroups and low HOXA gene expression as an adverse prognostic factor in pediatric ALL. Pediatr. Blood Cancer 55, 1072–1082 (2010).
Article PubMed Google Scholar
Trentin, L. et al. Two independent gene signatures in pediatric t(4;11) acute lymphoblastic leukemia patients. Eur. J. Haematol. 83, 406–419 (2009).
Article CAS PubMed Google Scholar
Chen, L. et al. Transcriptional diversity during lineage commitment of human blood progenitors. Science 345, 1251033 (2014).
Article PubMed PubMed Central CAS Google Scholar
Lee, K. Y. et al. Compound loss of muscleblind-like function in myotonic dystrophy. EMBO Mol. Med. 5, 1887–1900 (2013).
Article CAS PubMed PubMed Central Google Scholar
Wang, E. et al. Targeting an RNA-binding protein network in acute myeloid leukemia. Cancer Cell 35, 369–384 e367 (2019).
Article PubMed PubMed Central CAS Google Scholar
Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2013).
CAS PubMed Google Scholar
Heinz, S. et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol. Cell 38, 576–589 (2010).
CAS PubMed PubMed Central Google Scholar
Ray, D. et al. A compendium of RNA-binding motifs for decoding gene regulation. Nature 499, 172–177 (2013).
Article ADS CAS PubMed PubMed Central Google Scholar
Chen, J., Bardes, E. E., Aronow, B. J. & Jegga, A. G. ToppGene Suite for gene list enrichment analysis and candidate gene prioritization. Nucleic Acids Res. 37, W305–311 (2009).
Article CAS PubMed PubMed Central Google Scholar

Download references

Acknowledgements

We would like to thank Maurice Swanson, PhD, for providing the Mbnl1−/− transgenic mice. We are also grateful to Matthew Disney, PhD, for providing the small molecule MBNL1 inhibitor. The SH800S is supported by an NIH Shared Instrumentation Grant (S10OD023410). A.G. was supported by a CancerFree KIDS grant. N.S. was supported by an NIH grant (R01 CA226802). M.W. was supported by an NIH grant (R50 CA211404). A.R.K. was supported by a Hyundai Hope on Wheels grant. L.H.L. was supported by a CancerFree KIDS grant as well as an NIH grant (L40 HL143713-01). L.H.L. is a St. Baldrick’s Foundation Scholar.

Author information

These authors contributed equally: Svetlana S. Itskovich, Arun Gurunathan.

Authors and Affiliations

Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 45229, USA
Svetlana S. Itskovich, Jason Clark, Matthew Burwinkel & Ashish R. Kumar
Cancer and Blood Diseases Institute, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 45229, USA
Arun Gurunathan
Division of Experimental Hematology and Cancer Biology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 45229, USA
Mark Wunderlich
College of Medicine, University of Cincinnati School of Medicine, Cincinnati, OH, 45267, USA
Mikaela R. Berger
Department of Electrical Engineering and Computer Science, University of Cincinnati, Cincinnati, OH, 45221, USA
Aishwarya Kulkarni & Meenakshi Venkatasubramanian
Division of Biomedical Informatics, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 45229, USA
Aishwarya Kulkarni, Kashish Chetal, Meenakshi Venkatasubramanian & Nathan Salomonis
Department of Pediatrics, University of Cincinnati School of Medicine, Cincinnati, OH, 45229, USA
Nathan Salomonis, Ashish R. Kumar & Lynn H. Lee
Division of Oncology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 45229, USA
Lynn H. Lee

Authors

Svetlana S. Itskovich
View author publications
You can also search for this author in PubMed Google Scholar
Arun Gurunathan
View author publications
You can also search for this author in PubMed Google Scholar
Jason Clark
View author publications
You can also search for this author in PubMed Google Scholar
Matthew Burwinkel
View author publications
You can also search for this author in PubMed Google Scholar
Mark Wunderlich
View author publications
You can also search for this author in PubMed Google Scholar
Mikaela R. Berger
View author publications
You can also search for this author in PubMed Google Scholar
Aishwarya Kulkarni
View author publications
You can also search for this author in PubMed Google Scholar
Kashish Chetal
View author publications
You can also search for this author in PubMed Google Scholar
Meenakshi Venkatasubramanian
View author publications
You can also search for this author in PubMed Google Scholar
Nathan Salomonis
View author publications
You can also search for this author in PubMed Google Scholar
Ashish R. Kumar
View author publications
You can also search for this author in PubMed Google Scholar
Lynn H. Lee
View author publications
You can also search for this author in PubMed Google Scholar

Contributions

S.S.I., A.R.K., A.G. and L.H.L. conceived and designed the experiments. A.G., S.S.I., J.C., M.B., M.W., M.R.B. and L.H.L. performed experiments and analyzed experimental data. N.S. designed and oversaw bioinformatics analyses; N.S., K.C., A.K., and M.V. performed the informatics analyses. All authors contributed to the writing and editing of the manuscript.

Corresponding author

Correspondence to Lynn H. Lee.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Peer review information: Nature Communications thanks Bo Torben Porsen, Yi Xing and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Supplementary Information

Peer Review File

Description of Additional Supplementary Information

Supplementary Data 1

Supplementary Data 2

Supplementary Data 3

Supplementary Data 4

Supplementary Data 5

Reporting Summary

Source data

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Cite this article

Itskovich, S.S., Gurunathan, A., Clark, J. et al. MBNL1 regulates essential alternative RNA splicing patterns in MLL-rearranged leukemia. Nat Commun 11, 2369 (2020). https://doi.org/10.1038/s41467-020-15733-8

Download citation

Received: 27 January 2019
Accepted: 25 March 2020
Published: 12 May 2020
DOI: https://doi.org/10.1038/s41467-020-15733-8

This article is cited by

Bone-marrow-homing lipid nanoparticles for genome editing in diseased and malignant haematopoietic stem cells
- Xizhen Lian
- Sumanta Chatterjee
- Daniel J. Siegwart
Nature Nanotechnology (2024)
The function and mechanisms of action of circular RNAs in Urologic Cancer
- Zi-hao Zhang
- Yue Wang
- Ding-Wei Ye
Molecular Cancer (2023)
Circular RNAs in renal cell carcinoma: from mechanistic to clinical perspective
- Chunjie Huang
- Pooya Esfani Sarafraz
- Majid Nazari
Cancer Cell International (2023)
RNA binding proteins in MLL-rearranged leukemia
- Tiffany M. Tran
- Dinesh S. Rao
Experimental Hematology & Oncology (2022)
Distribution of alternative untranslated regions within the mRNA of the CELF1 splicing factor affects its expression
- Arkadiusz Kajdasz
- Daria Niewiadomska
- Krzysztof Sobczak
Scientific Reports (2022)

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.